187 related articles for article (PubMed ID: 24034811)
1. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.
Ricketts CJ; Morris MR; Gentle D; Shuib S; Brown M; Clarke N; Wei W; Nathan P; Latif F; Maher ER
Clin Epigenetics; 2013 Sep; 5(1):16. PubMed ID: 24034811
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
3. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Clarke N; Brown M; Kishida T; Yao M; Teh BT; Latif F; Maher ER
Br J Cancer; 2008 Jan; 98(2):496-501. PubMed ID: 18195710
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
5. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.
Morris MR; Ricketts C; Gentle D; Abdulrahman M; Clarke N; Brown M; Kishida T; Yao M; Latif F; Maher ER
Oncogene; 2010 Apr; 29(14):2104-17. PubMed ID: 20154727
[TBL] [Abstract][Full Text] [Related]
6. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
7. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
McRonald FE; Morris MR; Gentle D; Winchester L; Baban D; Ragoussis J; Clarke NW; Brown MD; Kishida T; Yao M; Latif F; Maher ER
Mol Cancer; 2009 Jun; 8():31. PubMed ID: 19493342
[TBL] [Abstract][Full Text] [Related]
8. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
[TBL] [Abstract][Full Text] [Related]
9. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.
Christoph F; Kempkensteffen C; Weikert S; Köllermann J; Krause H; Miller K; Schostak M; Schrader M
Br J Cancer; 2006 Dec; 95(12):1701-7. PubMed ID: 17133271
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
11. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic inactivation of the SLIT2 gene in gliomas.
Dallol A; Krex D; Hesson L; Eng C; Maher ER; Latif F
Oncogene; 2003 Jul; 22(29):4611-6. PubMed ID: 12881718
[TBL] [Abstract][Full Text] [Related]
14. [Aberrant methylation of tumor suppressor genes in renal cell carcinoma].
Zhang Q; Jin J; Tao Q
Ai Zheng; 2007 Nov; 26(11):1276-80. PubMed ID: 17991333
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Ricketts CJ; Gentle D; McRonald F; Carli N; Khalili H; Brown M; Kishida T; Yao M; Banks RE; Clarke N; Latif F; Maher ER
Oncogene; 2011 Mar; 30(12):1390-401. PubMed ID: 21132003
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
19. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.
Ying J; Li H; Seng TJ; Langford C; Srivastava G; Tsao SW; Putti T; Murray P; Chan AT; Tao Q
Oncogene; 2006 Feb; 25(7):1070-80. PubMed ID: 16247458
[TBL] [Abstract][Full Text] [Related]
20. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.
Yamashita K; Kim MS; Park HL; Tokumaru Y; Osada M; Inoue H; Mori M; Sidransky D
Mol Cancer Res; 2008 Jan; 6(1):31-41. PubMed ID: 18234960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
